This Biotechsees shares rise from $1 to over $11 and there may be no end in sight…

Catalysts are piling up for this fast-growing biotech company which may be one of the biggest biotech darlings in the making. As regenerative medicine continues to find its way into the mainstream, emerging biotech company BioStem Technologies, Inc. (OTC: BSEM) is making waves for its focus on harnessing elements of perinatal tissue derived from the human placenta for manufacturing structural tissue allografts to heal wounds. This includes a curated suite of versatile products called Vendaje. The company has been capturing Wall Street's attention as its share price has risen from around $1 in July of 2023 to as high as $7.00 by year-end. This year share prices have exceeded $9! One of the most exciting catalysts for potential growth comes from a recent price target increase from notable research firm Zack's Small Cap Research. It comes shortly after the company released preliminary and unaudited numbers that showed net revenue for 4Q2023 of $11.5 million, a more than 1300% increase from the year ago period! It wasn't that long ago that BioStem Technologies, Inc. (OTC: BSEM) was given a $9.25 price target from Zack's Small Cap research. Today that price target is at $18.70! The firm has written that "Investors are starting to agree with our view as the stock has moved solidly higher over the past year, moving up over 140%, while the Russell 2000 was roughly flat over the same period. The company really gained momentum in the second half of 2023 as BioStem was awarded a valuable Q code for Vendaje AC by the Centers for Medicare and Medicaid Services and solidified its funding situation. Recently, the company announced that its Healthcare Common Procedure Coding System code for Vendaje AC became effective and that the Center for Medicare Services established national pricing for AmnioWrap2 in all 50 states and territories." Zack's Small Cap Research believes that BioStem has a solid foothold in that tough to break into community and the acceptance and use of the company's products will continue to accelerate. Discover why there could be further upside ahead for BioStem Technologies in 2024! DISCLAIMER: Stocks and options trading have large potential rewards, but also large potential risk. You must be aware of the risks and be willing to accept them in order to invest in the stocks and options markets. Don't trade with money you can't afford to lose. This is neither a solicitation nor an offer to Buy/Sell stocks or options. No representation is being made that any account will or is likely to achieve profits or losses similar to those discussed in this report. The past performance of any trading system or methodology is not necessarily indicative of future results. All trades, patterns, charts, systems, etc., discussed in this report are for illustrative purposes only and not to be construed as specific advisory recommendations. Information contained in this correspondence is intended for informational purposes only and was obtained from sources believed to be reliable. Information is in no way guaranteed. No guarantee of any kind is implied or possible where projections of future conditions are attempted.

UpTrendAlerts, 711 SW 24th Ave, Boynton Beach, FL 33435, United States You may unsubscribe or change your contact details at any time. Powered by: